| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CASI Stock Overview
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally.
Rewards
Risk Analysis
CASI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.72 |
| 52 Week High | US$12.30 |
| 52 Week Low | US$2.24 |
| Beta | 0.44 |
| 1 Month Change | -27.85% |
| 3 Month Change | -4.90% |
| 1 Year Change | -76.55% |
| 3 Year Change | -91.20% |
| 5 Year Change | -91.71% |
| Change since IPO | -99.84% |
Recent News & Updates
Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Casi Pharmaceuticals (NASDAQ:CASI) is selling its equity interest of 12.0098% in Juventas Biotechnology (Tianjin) to Shenzhen Jiadao Gongcheng Equity Investment Fund for RMB240.87M (~$34.03M). Casi's unit Casi Biopharmaceuticals (Wuxi) signed the equity transfer agreement with Jiadao under which one payment will be made after signing and the second after the equity transaction is completed, the Rockville, Md.-based company said in a Sept. 23 press release. "The completion of the equity transfer transaction will strengthen CASI's balance sheet by providing CASI with sufficient cash to operate until, at least, the end of 2023," said Casi's Chairman and CEO Wei-Wu He. The CEO added that Casi expects Juventas to file an application an application to the Chinese drug regulator seeking approval of CNCT-19 for B-cell acute lymphoblastic leukemia. "CASI and Juventas will continue to maintain a working partnership, focusing on product launch and co-marketing for CNCT-19," the CEO commented.
CASI Pharmaceuticals Q2 2022 Earnings Preview
CASI Pharmaceuticals (NASDAQ:CASI) is scheduled to announce Q2 earnings results on Friday, August 12th, before market open. The consensus EPS Estimate is -$0.61 (-1120.0% Y/Y) and the consensus Revenue Estimate is $7.87M (+9.9% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Shareholder Returns
| CASI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | 5.1% | 4.4% |
| 1Y | -76.6% | -20.8% | -18.2% |
Return vs Industry: CASI underperformed the US Biotechs industry which returned -20.8% over the past year.
Return vs Market: CASI underperformed the US Market which returned -18.2% over the past year.
Price Volatility
| CASI volatility | |
|---|---|
| CASI Average Weekly Movement | 16.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CASI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: CASI's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 176 | Wei-Wu He | https://www.casipharmaceuticals.com |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome.
CASI Pharmaceuticals, Inc. Fundamentals Summary
| CASI fundamental statistics | |
|---|---|
| Market Cap | US$37.01m |
| Earnings (TTM) | -US$32.10m |
| Revenue (TTM) | US$34.91m |
1.1x
P/S Ratio-1.2x
P/E RatioIs CASI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CASI income statement (TTM) | |
|---|---|
| Revenue | US$34.91m |
| Cost of Revenue | US$14.53m |
| Gross Profit | US$20.38m |
| Other Expenses | US$52.48m |
| Earnings | -US$32.10m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.36 |
| Gross Margin | 58.39% |
| Net Profit Margin | -91.97% |
| Debt/Equity Ratio | 1.1% |
How did CASI perform over the long term?
See historical performance and comparison